Dizhi Pharmaceuticals: Suvotinib is listed in the US but has not started sales. Therefore, the current US tariff on new drugs has no effect.

According to the Di Zhe Pharmaceutical Securities Department, the company Shuwo Tinib was listed in the United States last year, but has not yet been commercialized in the United States, so the announcement of the United States to impose a 100% tariff on imported patented drugs and pharmaceutical ingredients will have no impact on the company. When asked whether this will affect commercialization expectations and pricing, their response was "Please wait for further announcements, it is not convenient to disclose now." The White House of the United States issued a notice on the 2nd, stating that President Trump signed a document on that day to impose a 100% tariff on imported patented drugs and pharmaceutical ingredients.